Continue to site >
Trending ETFs
You have successfully subscribed to Advisor Access. Thank you!
Help us personalize your experience.
Which type of investor describes you best?
Help us personalize your experience.
What is your AUM?
Knowing your investable assets will help us build and prioritize features that will suit your investment needs.

Congratulations on personalizing your experience.

Email is verified. Thank you!

What the Actavis Acquisition of Allergan Means for Mutual Fund Investors (AGN, ACT)

Shauna O'Brien

|

Allergan image
On Monday morning, Actavis (ACT) reported that it has agreed to acquire Allergan (AGN) for approximately $66 billion in a cash and stock deal.

Inside the Deal

The $66 billion deal would create one of the top 10 global pharmaceutical companies by revenue. The deal comes after Allergan was faced with an unwanted takeover from Valeant in April, which was valued at $54 billion.

With this size, this acquisition would be one of the largest deals made in 2014.

Mutual Funds to Watch

Symbol Mutual Fund Exposure Stake
VTSMX Vanguard Total Stock Market Index Allergan 1.69%
VFINX Vanguard 500 Index Allergan 1.04%
VGHCX Vanguard Health Care Actavis 3.23%
VTSMX Vanguard Total Stock Market Index Actavis 1.63%

The Bottom Line

This deal adds to the many major acquisitions that have already taken place in 2014 and is likely to be one of the biggest acquisitions this year. Major news events are very important for mutual fund investors to be aware of – even if the funds you own only have a small stake in the affected companies.

Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.

Popular Articles

Read Next

Allergan image

What the Actavis Acquisition of Allergan Means for Mutual Fund Investors (AGN, ACT)

Shauna O'Brien

|

On Monday morning, Actavis (ACT) reported that it has agreed to acquire Allergan (AGN) for approximately $66 billion in a cash and stock deal.

Inside the Deal

The $66 billion deal would create one of the top 10 global pharmaceutical companies by revenue. The deal comes after Allergan was faced with an unwanted takeover from Valeant in April, which was valued at $54 billion.

With this size, this acquisition would be one of the largest deals made in 2014.

Mutual Funds to Watch

Symbol Mutual Fund Exposure Stake
VTSMX Vanguard Total Stock Market Index Allergan 1.69%
VFINX Vanguard 500 Index Allergan 1.04%
VGHCX Vanguard Health Care Actavis 3.23%
VTSMX Vanguard Total Stock Market Index Actavis 1.63%

The Bottom Line

This deal adds to the many major acquisitions that have already taken place in 2014 and is likely to be one of the biggest acquisitions this year. Major news events are very important for mutual fund investors to be aware of – even if the funds you own only have a small stake in the affected companies.

Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.

Popular Articles

Read Next

Advertisement

×

Wait! Do you know all the important aspects of mutual funds?

×

Free Advisor Access newsletter emailed to you.

Receive free and exclusive email updates for financial advisors about best performers, news, CE accredited webcasts and more.

Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.

Disclaimer: By registering, you agree to share your data with MutualFunds.com and opt-in to receiving occasional communications about projects and events. The contents of this form are subject to the MutualFunds.com Privacy Policy. You can unsubscribe at any time.